Brief: Phasebio Pharma Announces Deal With Viamet Pharma And Unit Selenity Pharma

PhaseBio Pharmaceuticals

13/01/2020 21:34

Jan 13 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO ANNOUNCES ACQUISITION OF NOVEL ORAL ALDOSTERONE
SYNTHASE INHIBITOR TO DEVELOP FOR TREATMENT-RESISTANT
HYPERTENSION
    * PHASEBIO PHARMACEUTICALS - AGREEMENT WITH VIAMET
PHARMACEUTICALS
HOLDINGS, LLC AND ITS UNIT, SELENITY PHARMACEUTICALS (BERMUDA),
LTD.
    * PHASEBIO PHARMACEUTICALS - WILL DESIGNATE LEAD DEVELOPMENT
COMPOUND AS PB6440, WHICH PHASEBIO PLANS TO DEVELOP FOR
TREATMENT-RESISTANT HYPERTENSION
    * PHASEBIO PHARMACEUTICALS - AGREEMENT TO ACQUIRE ALL OF
ASSETS,
INTELLECTUAL PROPERTY RIGHTS RELATED TO CERTAIN NOVEL
ALDOSTERONE SYNTHASE INHIBITORS
    * PHASEBIO PHARMACEUTICALS - AGREEMENT TO ACQUIRE ALL OF
ASSETS,INTELLECTUAL PROPERTY RIGHTS INCLUDING CO'S DEVELOPMENT
COMPOUND EARLIER CALLED SE-6440
    * PHASEBIO PHARMACEUTICALS - TERMS OF AGREEMENT INCLUDE AN
UPFRONT
PAYMENT BY PHASEBIO
    * PHASEBIO PHARMACEUTICALS - CO WILL BE RESPONSIBLE FOR ALL
DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF PB6440

Source text for Eikon:  ID:nGNX7G1Qw4 
Further company coverage:  PHAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))